UPDATE 1-FDA panel says Cubist anti-infective shows efficacy, safety

March 31 (Reuters) - Cubist Pharmaceuticals Inc's anti-infective tedizolid for acute bacterial skin infections shows substantial evidence of safety and efficacy, an advisory panel to the U.S. Food and Drug Administration concluded on Monday.